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Abstract 
Cancer-associated FRK mutations have not been thoroughly studied however, a previous study 
analyzed six cancer related mutations of BRK L16F, R131L, V253M, N317S, L343F, P450L; and 
it was found that there are similar residues in FRK. We identified R64P, K87N, S145R, K265R, 
N359I, del V378-F379 (VF) found in breast cancer, large intestine cancer, ovarian cancer, and 
liver cancer. This study analyzes the effect of the mutation of these similar residues in the BRK 
study, as well as uncharacterized cancer related mutations of FRK.  Mutating two of the similar 
residues maintained the same effects in BRK and FRK whereas the remaining mutants in FRK had 
no effect on activity. The uncharacterized cancer related mutations of FRK produced interesting 
results where the mutations in kinase domain (K265R, N359I, del VF) reduced, inactivated and 
increased kinase activity respectively. Proliferation, migration and invasion assays were also 
performed with the R64P, K265R, N358I and VF mutations. The proliferation data revealed that 
the cell line expressing wild type FRK reduced cell growth which is consistent with past findings. 
The other mutations also resulted in reduced cell growth in MDA-MB-231 breast cancer cells but 
were not significantly different to wild type FRK. The invasion assay results show that the wild 
type FRK significantly reduced invasion compared to the MDA-MB-231 cells compared to 
parental controls. Differing from the proliferation assay, the mutations R64P, K265R, N359I, and 
VF showed no reduction in cell invasiveness compared to the parental. The mutations expressed 
transiently in HEK293 were found to only impact STAT3 phosphorylation where all FRK 
constructs induced STAT3 phosphorylation except for N359I. Binding experiments were 
performed using rotational anisotropy and four peptides derived from FRK C terminus 
(ETDSS(pY)SDANN), SH2 consensus binding sequence (HF(pY)ENI), PTEN 
(PNVEEPSNPEASSS), and BRCA1 (DTYLIPQIPHSHY).  The wild type SH2 domain was able 
of binding to both peptides from the FRK C terminus and the SH2 consensus binding sequence 
with a Kd of 2.5 M and 0.4 M respectively. The S145R SH2 domain was also capable of 
interacting with both peptides with a Kd of 1.4 M with the FRK C terminus and 0.8 M with the 
SH2 consensus binding sequence. Unfortunately, the SH3 domain was unable to bind to the 
sequences selected.  
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1.0 Introduction 
1.1 Cancer and Tyrosine Kinases 
Cancer arises from a series of mutations that dysregulate the cells response to extracellular signals 
and allow the cell to grow without outside signaling (Hanahan and Weinberg, 2011). Tyrosine 
kinases mediate the response to growth signaling factors (Hanahan and Weinberg, 2011). Their 
activity is strictly regulated in normal cells but can acquire transforming roles due to mutations 
which result in increased cell proliferation, migration and invasion. Transforming activity can be 
caused from mutations, fusions, or amplifications. Mutations in EGFR which lack amino acids 6-
273, give the receptor constitutive activation (Zalutsky, 1997). The BCR-Abl fusion has been 
studied in CML where the first exon if Abl is replaced with BCR sequences which results in 
constitutive activity (An et al., 2010). Lastly, amplification is a mechanism which heightens 
activity due to increased protein level. Proteins such as HER2 which is overexpressed in certain 
breast cancers due to gene amplification and EGFR which is over expressed in a series of cancers 
(Menard et al., 2000). Tyrosine kinases have been seen to play critical roles in cancers and have 
become major therapeutic targets which shows the importance of this protein family in both normal 
and cancer cells. 
1.2 Tyrosine Kinases: 
Tyrosine kinases are a diverse group of proteins which play a role in a number of cellular processes 
through the mediation of signaling cascades such as growth, differentiation, migration, invasion, 
apoptosis and metabolism (Paul and Mukhopadhyay, 2004). This family is made up of 90 total 
proteins and is divided into two major groups; receptor tyrosine kinases (RTK) and non-receptor 
tyrosine kinases. Of these 90 tyrosine kinases, 58 are receptor tyrosine kinases which form 20 
subfamilies and 32 are non-receptor (NRTK) which are organized into 10 different subfamilies 
(Robinson et al., 2000).  The RTKs are membrane spanning proteins which possesses a ligand 
binding site on the extracellular side and a kinase domain on the intracellular side than participates 
in auto and transphosphorylation following ligand binding and dimerization. Non-receptor 
tyrosine kinases are cytosolic kinases whose structure and localization can vary. The kinase 
domain of the NRTKs spans approximately 300 amino acid residues and form 2 distinct lobes, the 
N and C lobes. The binding site for ATP is located in a cleft in between the two lobes (Paul and 
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Mukhopadhyay, 2004). The RTKs are the starting point of signaling events in response to 
extracellular signals where the NRTKs participate in signaling events downstream of the RTKs.  
1.2.1 SRC Family Kinases:  
The Src family of tyrosine kinases (SFKs) is perhaps the best studied group of tyrosine kinases. 
This family of kinases plays critical roles in cell signaling, cell division, motility, adhesion, 
angiogenesis and survival (Summy and Gallick, 2003). The Rous Sarcoma Virus, which is capable 
of generating tumors within chickens, was first discovered in 1911 by Peyton Rous (Rous, 1911). 
The transforming characteristics of this virus were found to be induced by a protein called Src. 
There were also two variants of this gene, v-Src the oncogene, and c-Src the proto oncogene (Smart 
et al., 1981). V-Src is an unregulated form of Src which lacks a C-terminal tail and regulatory 
tyrosine. The SFK is made up of 9 NRTKs those being, c-Src, c-Yes, Fyn, Lyn, Lck, Hck, Blk, 
Fgr, and Yrk.  This family of proteins is distinguished by the presence of three conserved domains, 
the SH3, SH2, and Kinase domains as well as eleven exons (Cetkovic et al., 2004).  
 
 
Figure 1. 1 
Src structure schematic showing SH3, SH2, and kinase domains and N terminal myristoylation 
site. Numbers on the bottom indicate the starting and ending amino acid residue for each respective 
domain and numbers on top indicate important residues. Lysine 298 (K298) is the ATP contacting 
residue, Tyrosine 419 (Y342) is the autophosphorylation site and Tyrosine 530 is the C terminal 
regulatory tyrosine.  
1.2.2 Src Regulation: 
C-Src is regulated through phosphorylation of a specific tyrosine residue Y530 in the C-terminal 
tail which is conserved in other family members (Cooper et al., 1986).When Y530 becomes 
phosphorylated, the C-terminal tail can interact with the SH2 domain of c-Src. This interaction 
between the C-terminus and the SH2 domain lock c-Src in an inactive conformation. The SH3 
domain also interacts with the poly-proline rich region between the SH2 and kinase domain in 
order to aid repression of enzymatic activity (Cooper et al., 1986; Cooper and Howell, 1993). An 
additional critical tyrosine was also identified, which when phosphorylated causes c-Src to become 
active. This tyrosine is Y419 located within the kinase domain (Jove and Hanafusa, 1987). 
SH3 SH2 Kinase 
84 145 151 248 270 523 536 
Src 
K298 Y419 Y530 
Myr 
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Additional conserved amino acids are also found in the kinase domain of Src. The lysine 298 is 
responsible for the interaction with ATP where the kinase domain can then facilitate the 
breakdown of ATP to ADP and phosphorylate its target tyrosine (Luttrell et al., 1996). Src 
possesses an N-terminal myristoylation site but all of the Src family kinases possess either 
myristoylation or palmitoylation signals which localizes the NRTK to the membrane where it can 
interact with its targets (Buss et al., 1986).  
 
Figure 1. 2 
Regulation of the Src kinase through phosphorylation. As presented when tyrosine 527 (530 in 
Humans) becomes phosphorylated and interacts with the SH2 domain. The SH3 domain then 
interacts with a region between the SH2 and kinase domain. Intramolecular interactions between 
the SH3 and SH2 domain lock the enzyme in an inactive conformation. This inactivation can be 
reversed through the dephosphorylation of tyrosine 527 and the enzyme can become active through 
the autophosphorylation of tyrosine 416 (Y419 in Humans) (Martin, 2001). 
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1.2.3 SH3 Domain: 
The Src homology 3 (SH3) domain is conserved among all Src family and related kinases. This 
domain is roughly 60 amino acids in length and was first identified towards the N terminus separate 
from the catalytic domains in Src tyrosine kinases (Mayer et al., 1988). This domain facilitates 
interactions of SFKs with signaling receptors and participate in inter/intramolecular interactions. 
SH3 domains are composed of a five stranded -sandwich and a short helix (Saksela and Permi, 
2012). The original consensus sequences was identified to be PXXP (P being proline and “X” 
being any of the 20 amino acids) (Ren et al., 1993). It was also found that the PXXP motif could 
bind in two different conformations depending on the placement of a positive amino acid such as 
lysine or arginine (Feng et al., 1994; Yu et al., 1994). The two orientations are K/RxxPxxP or 
xPxxPxK/R which are referred to as type I and type II respectively (Lim et al., 1994). Both of these 
peptide types possess the PxxP base motif and binds to SH3 domains which is mainly hydrophobic 
due to the surface aromatic amino acids (Lim et al., 1994). There also exists an additional binding 
pocket referred to as the specificity pocket which will bind to the N terminus of the type I peptide 
and the C terminus of the type II peptides. This pocket interacts with the positively charged amino 
acids of either type I or type II peptides and is therefore negatively charged (Feng et al., 1994).  
The PI3K SH3 domain has been bound to a type II peptide and structure based mutations were 
generated (Yu et al., 1994). Since both PI3K and Src bind peptides with N terminal arginines 
mutations of conserved residues between PI3K and Src were generated to observe changes in 
peptide binding.  The peptide RKLPPRPSK was referred to as RP1 by Yu et al. (1994) and the 
acidic residues of the domain which interact with the first and sixth arginine were mutated. These 
mutations were E19Q D21N, E51Q in PI3K with those residues also being conserved in Src. It 
was found that the aspartate mutations D21N had the most drastic effect on peptide affinity where 
the KD was far increased indicating a less tight interaction (Yu et al., 1994). 
1.2.4 SH2 Domain:  
The Src homology 2 (SH2) domain, much like the SH3 domain is a non-catalytic domain of 
approximately 100 amino acids in length that is associated with the interaction of SFKs with 
signaling receptors and molecules as well as intramolecular interactions (Russell et al., 1992; 
Sadowski et al., 1986).  These domains have been found in all SFKs, but also a number of signaling 
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molecules near the plasma membrane which facilitate the intracellular transduction of extracellular 
signals. The structure of this domain is relatively conserved with a five stranded anti-parallel -
sheet core sandwiched between two alpha helices extended by a -strand and small triple stranded 
-sheet (Waksman et al., 1992).  Sequence alignment studies have also been performed and show 
a short sequence of six amino acids was found to be highly conserved. That sequence in Src is 
FLVRES and FLIRES in FRK (Campbell and Jackson, 2003).  Of the conserved motifs, this 
sequence has been implicated in the facilitation of phosphotyrosine binding. Certain amino acids 
in this conserved sequence may play a larger role in phosphotyrosine binding. The arginine of this 
motif was mutated in Src and resulted in the inhibition of phosphotyrosine binding (Bibbins et al., 
1993). The serine had also been mutated in Abl kinase where it then lost its ability to transform 
fibroblasts where the wild type Able kinase was capable of initiating transformation. It was 
reasoned that the inability to transfom fibroblasts was reduced binding to phosphotyrosines (Mayer 
et al., 1992). Several of the amino acids in the sequence FLVRESES in Src were mutated and seen 
to have decreased phosphotyrosine binding those mutations with proposed reduced binding were 
R171K, S173C, and S175C. the arginine was seen to have the greatest inhibition of 
phosphotyrosine binding (Mayer et al., 1992). 
Peptide specificity is quite variable across the different tyrosine kinase families and signaling 
molecules. A study in 2013 analyzed the differing sequence specificities of a number of Src related 
kinases including FRK, BRK and SRMS (Zhao et al., 2013). This study used randomized peptides 
in the order xxpYxxx, with the x indicating any of the 20 amino acids from the -2 position to the 
+3 position with the phosphotyrosine at position 0.  Src was found to preferentially bind to 
HYpYTMI, FRK to HFpYENI, BRK to HMpYDIC, and SRMS to HHpYHIC.  
1.3 BRK Family Kinase: 
The BRK family kinases (BFK) include three non-receptor tyrosine kinases which include FRK, 
BRK and SRMS. These three tyrosine kinases do not share a great deal of sequence similarity but 
are grouped together because of similar gene-splicing patterns. Src family kinases possess 11 
exons where FRK, BRK, and SRMS are comprised of 8 exons (Goel and Lukong, 2015; Serfas 
and Tyner, 2003). Much like the SFK family, the three BFK members possess SH3, SH2, and 
kinase domains (Goel and Lukong, 2015; Serfas and Tyner, 2003). The SH3 and SH2 domains are 
both non-catalytic and interact with protein targets, where the kinase domain functions to 
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phosphorylate the enzymes target tyrosine through the conversion of ATP to ADP. All three 
proteins in this family lack a myristoylation site which are found at the N-terminus of SFKs and 
are critical for their membrane association (Goel and Lukong, 2015; Serfas and Tyner, 2003).  
1.3.1 Breast Tumor Kinase (BRK): 
Breast tumor kinase (BRK) also known as PTK6 is a non-receptor kinase 451 amino acids in length 
and maps to chromosome 20. This enzyme is composed of 3 functional domains where the two N 
terminal domains, the SH3 and SH2 domains facilitate protein-protein interactions and the kinase 
domain phosphorylated its target substrate through the breakdown of ATP. Several amino acids 
are conserved through this family such as the ATP binding lysine and the autophosphorylation 
tyrosine. K219 is responsible for ATP binding and Y342 is the autophosphorylation site. BRK has 
oncogenic effects when over expressed in breast cancer and it has also been found that BRK is 
over expressed in over 80% of breast cancers, while it is not expressed in normal mammary glands 
(Barker et al., 1997). Regulation also occurs in a similar manner to the regulation of Src, where in 
BRK’s case tyrosine 342 is the autophosphorylation site and must be phosphorylated to become 
active. Tyrosine 447, located in the C terminus is the regulatory tyrosine and when phosphorylated 
interacts with the SH2 domain of BRK and locks the enzyme in an inactive conformation (Qiu and 
Miller, 2002).  
 
Figure 1. 3 
Breast tumor kinase (BRK) showing SH3, SH2, and kinase domains. Numbers on the bottom 
indicate the starting and ending amino acid residue for each respective domain and numbers on 
top indicate important residues. Lysine 219 (K219) is the ATP contacting residue, Tyrosine 342 
(Y342) is the autophosphorylation site and Tyrosine 447 is the C terminal regulatory tyrosine. 
This tyrosine is also conserved with FRK and SFKs. BRK null mice have also been generated in 
the past by the Tyner group (Haegebarth et al., 2006). BRK is expressed in healthy gut intestinal 
tissue, which is where the effects were noticed. There were increased rates of growth as the 
intestinal villi appeared longer than wild type. Also noted was a slower differentiation where 
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samples from the intestines of these mice showed decreased levels of intestinal fatty acid binding 
protein (Haegebarth et al., 2006). In 2012 a xenograft study was performed by the Lukong lab 
where wild type BRK and BRK Y447F, the constitutively active mutation, were stably expressed 
in MDA-MB-231 breast cancer cells and injected into mouse mammary fat pads (Miah et al., 
2012). Wild type BRK was capable of produce a slightly larger tumor than the control MDA-MB-
231 cell line, and the BRK Y447F mutation produced tumors three-fold larger than in the control 
mice. This indicates the BRK must be fully activated for these effects to be seen (Miah et al., 
2012).  
1.3.2 Src Related Kinase Lacking C Terminal Tyrosine and N Terminal Myristoylation 
Sites (SRMS): 
SRMS is a non-receptor tyrosine kinase 488 amino acids long and maps to chromosome 20 
adjacent to BRK (Kohmura et al., 1994). This kinase also possesses Src homology domains, SH3, 
SH2 and the kinase domain but lacks a C terminal tail. The lack of a C terminus indicates an 
alternative mechanism for enzymatic regulation. The SH3 and SH2 domains participate in protein-
protein interactions and the kinase domain phosphorylates SRMS’ target substrates. The amino 
acids responsible for ATP binding and autophosphorylation have been identified. K258 has been 
shown to interact with ATP and Y380 as the main autophosphorylation site required for activity. 
Mutation of K258 resulted in reduced autophsphorylation and mutation of Y380 resulted in 
reduced activity. SRMS is the most understudied protein of the BFKs and as a result its main 
function remains unknown. BRK and FRK have been studied closer than SRMS and their functions 
are somewhat understood. BRK has been seen to function as an oncogene and FRK is a candidate 
tumor suppressor in breast tissue. The Lukong lab has recently conducted a study on SRMS 
concerning its expression in breast cancer and its association with Dok1 (Goel et al., 2013). The 
study concluded that SRMS is overexpressed in breast cancer compared to the normal tissue. Also, 
that SRMS is an active kinase whose activity is regulated through interactions that requires its N 
terminus. Lastly Goel et al. determined that Dok1 is in fact a substrate of SRMS (Goel et al., 2013).  
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Figure 1. 4 
Src Related Kinase Lacking C Terminal Tyrosine and N Terminal Myristoylation Sites (SRMS) 
exhibiting its SH3, SH2 and kinase domains, extended N terminus and lack of a C terminus. 
Numbers on the bottom indicate the starting and ending amino acid residue for each respective 
domain and numbers on top indicate important residues. Lysine 258 (K258) is the ATP contacting 
residue, and Tyrosine 380 (Y380) is the autophosphorylation site. There is no regulatory tyrosine 
present as there is no C terminus however, SRMS’ N terminus is required for activity. 
1.4 Fyn Related Kinase (FRK): 
1.4.1 Gene Discovery 
FRK, also known as Rak, the Russian word for cancer, is a 54 kDa non-receptor tyrosine kinase 
which maps to the chromosomal locus 6p21-23 which is frequently deleted in cancer (Goel and 
Lukong, 2016). FRK was discovered in breast cancer through a search for novel kinases where 
conserved sequences of known kinase catalytic domains were used to amplify similar sequences 
of unknown kinase domains in order to identify them first named TKI along with additional kinase 
discovered. FRK was then cloned in a later study through polymerase chain reaction (PCR) from 
the liver cancer cell line HEP3B (Lee et al., 1994). This was done using primers which were based 
off tyrosine kinase (TYK) motifs. The product of these PCR reactions resulted in a 180 bp fragment 
which was then used to amplify full length cDNA. These resulting clones were a length of 2.9 kb 
and coded for a protein 505 amino acids in length. Several features were noticed which suggested 
that FRK functions as a kinase. Those being an ATP binding domain and a conserved motif 
(DLAARN) which suggested that FRK was a TYK and not a serine/ threonine kinase. The Src 
kinase family all possess SH3, SH2 and kinase domains, and both SH3 and SH2 domains were 
identified in FRK. The gene was also lacking a hydrophobic stretch of residues which place this 
kinase into the non-receptor group of TYKs. It was found that FRK possessed a 49% amino acid 
SH3 SH2 Kinase 
51 112 120 212 230 488 
K258 Y380 
SRMS 
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sequence similarity to Fyn kinase and a 47% identity to c-Src, and for that reason it was named 
Fyn-Related-Kinase (FRK) (Lee et al., 1994). 
1.4.2 Structure 
FRK is a 505 amino acid protein which is related to Src through its SH3, SH2 and kinase domains 
and is part of the BRK family of kinases which also includes BRK and SRMS. The SH3 and SH2 
domains are involved in protein-protein interactions. The SH3 domain will interact with the motif 
PXXP, while the SH2 domain will bind to phosphorylated tyrosines. There is a nuclear localization 
signal within the SH2 domain of FRK (KRLDEGGFFLTRRR) although it is expressed in the 
cytosol of epithelial cells (Cance et al., 1994). Several amino acids which are critical for function 
were also characterized. The study which initially identified FRK where they first analyzed its 
activity it was found that FRK was an active kinase with an auto phosphorylation site on tyrosine 
387 (Cance et al., 1994). 
 
 
 
 
 
 
 
 
Figure 1. 5 
Structure schematics of FRK and mouse ortholog IYK exhibiting SH3, SH2 and kinase domains. 
Also labelled is a nucleus localization site within the SH2 domain (NLS).  Numbers on the bottom 
indicate the starting and ending amino acid residue for each respective domain and numbers on 
top indicate important residues. Lysine 262 (K262) is the ATP contacting residue, Tyrosine 387 
(Y387) is the autophosphorylation site and Tyrosine 497 is the C terminal regulatory tyrosine. IYK 
possesses an N terminal myristoylation site as well as critical amino acids labelled Lysine 269 
(K269) is the ATP contacting residue, Tyrosine 384 is the autophosphorylation site and Tyrosines 
497 and 504 (Y4987, Y504) are regulatory tyrosines. 
SH3 SH2 Kinase 
42 110 116 208 234 491 505 
K262 Y387 Y497 
FRK 
NLS 
SH3 SH2 Kinase 
42 117 123 215 241 498 512 
K269 Y384 Y504 NLS 
IYK Myr 
Y497 
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FRK may be regulated in a similar manner to Src and BRK, where the C-terminal tyrosine 497 
binds to the SH2 domain once phosphorylated and the SH3 domain interacts with the SH2-Kinase 
linker region. This locks the enzyme in an inactive conformation preventing FRK from 
phosphorylating its target proteins. Studies have been performed on IYK, the mouse ortholog of 
FRK in which mutation of the C terminal tyrosine resulted in decreased activation (Oberg-Welsh 
et al., 1998). Although there are similarities between FRK and IYK, one noticeable difference is 
that IYK possesses an N terminal myristoylation site where FRK does not. This could indicate that 
the mouse FRK ortholog may have differing functions to FRK (Serfas and Tyner, 2003). 
Additional amino acid residues are conserved between these family members, those being the ATP 
binding lysine and autophosphorylation site located in the kinase domain (Figure 1). The 
autophosphorylation site (Y387 in FRK) must be phosphorylated for FRK to be fully activated.  
Lysine 262 is the residue responsible for ATP bind and mutation of K262 in FRK results in an 
inactive enzyme due to the loss of ATP binding (Cance et al., 1994; Meyer et al., 2003). There is 
also a highly conserved tryptophan (W227 in FRK) residue in the BFK family. Mutating this 
conserved tryptophan residue in BRK and SRMS results in an inactive enzyme. It is speculated 
that this residue interacts with the N lobe of the kinase and promotes its stability (Goel et al., 2013). 
The proteins in the BRK family may have differing functions as BRK has been described as an 
oncogene where it is overexpressed in 60% of breast cancers (Brauer and Tyner, 2010)where FRK 
behaves as a tumor suppressor in breast cancer and glioma cell lines due to its growth inhibitory 
effects (Goel and Lukong, 2016). SRMS is the last member of this family however its main roles 
have not yet been elucidated.  
 1.4.3 FRK Tumor Suppressor Role: 
The expression of FRK is decreased or lost in some breast cancers and gliomas, which may indicate 
its role as a potential tumor suppressor (Bagu et al., 2017; Zhou et al., 2012). The mechanism of 
the loss of FRK expression was investigated by our lab and it was found that promoter hyper-
methylation was responsible for the lost expression (Bagu et al., 2017). Localization also plays a 
large role in the functionality of this kinase in terms of modulating signaling in these cell lines. 
FRK has a nuclear localization signal in its SH2 domain however; it is detected primarily in the 
cytosol of breast cancers. Nuclear FRK may be responsible for its growth inhibitory function as it 
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is localized to the cytosol in the proliferative follicular phase of the menstrual cycle and localized 
to the nucleus post ovulation during the luteal phase (Berclaz et al., 2000). FRK has also been seen 
to interact with Phosphatase and tensin homolog (PTEN) in breast cancer which is a negative 
regulator of AKT signaling (Brauer and Tyner, 2009). PTEN functions by dephosphorylating 
phosphatidylinositol 3, 4, 5 tri phosphate (PIP3) which prevents AKT activation. FRK 
phosphorylates PTEN on Y336 and this phosphorylation  prevents PTEN from being degraded by 
NEDD4 and results in reduced activation of AKT signaling and reduced cell proliferation (Brauer 
and Tyner, 2009). Much like the interaction with PTEN, FRK phosphorylated BRCA1 on Y1552 
which prevents proteasome mediated degradation of BRCA1 (Kim et al., 2015). This 
phosphorylation of BRCA1 by FRK prevents the accumulation of DNA damage (Kim et al., 2015). 
An interaction has also been seen between FRK and EGFR. EGFR function can be modulated 
through phosphorylation of tyrosine 1173 by FRK. This phosphorylation event may reduce EGFR 
activity through the reuptake of EGFR into vesicles and degradation. When analyzing how FRK 
binds to EGFR it was found that deletion of either the SH3 or SH2 domain resulted in a stronger 
interaction between FRK and EGFR. The significance of this remains unknown (Jin and Craven, 
2014).  FRK may function as a tumor suppressor in glioma as it has been seen to decrease the 
levels of phospho JNK and c-Jun (Zhou et al., 2012). Growth inhibitory effects have also been 
seen in glioma where FRK prevents nuclear cyclin D accumulation which promotes G1 cell cycle 
arrest (Hua et al., 2014). The expression of FRK also increased the levels of N-cadherin in glioma 
thus promoting the N-cadherin/ b-Catenin complex. This interaction results in decreased cell 
proliferation, and migration (Shi et al., 2015).  
1.4.4 FRK Oncogenic Role: 
Although the majority of studies exhibit FRK’s tumor suppressor role in breast cancer and glioma, 
a study was performed investigating FRK’s role in liver cancer. This study analyzed a number of 
FRK activating mutations located in the kinase domain which suggest that FRK may function as 
an oncogene in hepatocellular carcinoma. The activating FRK mutations del V378-F379 and del 
V378-K380 produced high levels of phosphorylated STAT3 and were capable of forming tumors 
in xenograft mouse models (Pilati et al., 2014).   
Several FRK fusion proteins have been identified which possess oncogenic properties. A fusion 
protein between ETV6 and the kinase domain of FRK was identified in a patient with acute 
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myelogenous leukemia (AML).  In this fusion protein, exon 4 of ETV6 is fused to exon 3 of FRK 
which comprises the oligomerization domain of ETV6 and the kinase domain of FRK. It was found 
that ETV6/FRK could transform Ba/F3 and NIH3T3 cells in a kinase dependent manner indicating 
that this fusion protein can contribute to leukemogenesis (Hosoya et al., 2005). 
 A second FRK fusion protein has been identified with Caprin1 in ALK-negative anaplastic large 
cell lymphoma (ALCL). Caprin1 is a cell cycle associated protein that is expressed in lymphocytes 
and found expressed in ALCLs. In this case Caprin1 has become fused to exon 3-8 of FRK, with 
a break point at residue 156 in the SH2 domain. The fusion between Caprin1 and FRK was capable 
of inducing STAT3 phosphorylation in Ba/F3 and HEK 293T. It was also noted that the function 
of this fusion protein was inhibited by the kinase inhibitor dasatinib, which may indicate that these 
FRK rearrangements could be possible candidates for novel therapeutic treatments (Hu et al., 
2018). 
1.4.5 FRK Interaction Partners: 
FRK has been confirmed to interact with proteins such as PTEN, EGFR, and BRCA1. The SH2 
domain of FRK has also been characterized for its binding specificity through binding a 
phosphotyrosine peptide with random amino acids in positions -2 to +3 with the phosphotyrosine 
at position 0. The preferred peptide of the FRK SH2 domain is HFpYENI. There is also some 
overlap in the amino acid sequence of the preferred peptide between the three BFK members, but 
certain residues will dictate how the FRK SH2 domain forms interactions with its specific binding 
partners (Zhao et al., 2013).  
The retinoblastoma protein (pRB) was the interaction of FRK that was first characterized that 
yielded the first possibility that FRK was a tumor suppressor since the transfection of FRK into 
NIH 3T3 cells resulted in a reduced number of colonies being formed (Craven et al., 1995). pRB 
is a protein which functions to regulate the cell cycle, through the binding of E2F thus inhibiting 
their function. This keeps the cell in the G1 phase (Weinberg, 1995). This regulation of cell cycle 
and repression of E2F occurs when pRB is hypophosphorylated, however, CDK4/Cyclin D form 
a complex where it phosphorylates pRB. When pRB is hyperphosphorylated it can no longer bind 
E2F and the cell cycle is allowed to proceed (Weinberg, 1995). FRK was seen to associate with 
pRB within the A/B pocket. The significance of this interaction has not yet been elucidated 
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however speculation may suggest that this interaction brings FRK into proximity of other targets 
(Craven et al., 1995).  
The interaction between FRK and phosphatase and tensin homolog deleted from chromosome 10 
(PTEN) has been previously characterized. PTEN is a tumor suppressor gene located on 
chromosome 10 that is frequently deleted in a number of cancers including breast cancer (Li et al., 
1997). PTEN functions to inhibit the AKT signaling pathway, where PTEN’s phosphatase activity 
dephosphorylates phosphatidylinositol 3, 4,5-triphosphate which regulates the activity of AKT and 
represses the cell survival and growth initiation responses (Cantley and Neel, 1999). It was 
discovered that FRK interacted directly with PTEN through the SH3 domain of FRK and the C2 
domain or phosphatase domain of PTEN (Yim et al., 2009). Yim et al. also characterized the 
phosphorylation of PTEN by FRK on tyrosine residue 336 which resulted in the increased stability 
and decreased association with NEDD4 which reduces degradation of PTEN (Yim et al., 2009). 
EGFR EGFR (epidermal growth factor receptor) has also been studied as an interaction partner of 
FRK. is a membrane spanning ligand receptor tyrosine kinase that upon stimulation with its ligand 
(EGF) EGFR receptors dimerize and participate in auto and transphosphorylation.  This receptor 
tyrosine kinase then functions as a docking site for proteins such as Grb2 which further transduces 
extracellular signals (Giubellino et al., 2008). Jin and Craven revealed that there was a direct 
interaction between FRK and EGFR (Jin and Craven, 2014). Experiments similar to the PTEN 
interaction study were then conducted where domain deletions of FRK were constructed in order 
to identify which domain participated in the interaction. When either the SH3 or SH2 domains 
were deleted it did not alter the interaction between FRK and EGFR although only the 
simultaneous deletion of both binding domains resulted in a decreased interaction. This result 
suggests that the domains must bind to EGFR cooperatively in order to interact with EGFR.  
Phosphorylation of tyrosine 1173 on EGFR contributes to the internalization of the membrane 
receptor (Keilhack et al., 1998; Sorkin and Goh, 2009). FRK was shown to phosphorylate this 
tyrosine residue and reduce the concentration of EGFR at the plasma membrane (Jin and Craven, 
2014) 
Recently FRK was noted to interact with tumor suppressor BRCA1 in a similar manner to PTEN. 
BRCA1 is a tumor suppressor that plays critical roles in the cell cycle, DNA repair and apoptosis 
(Snouwaert et al., 1999; Thangaraju et al., 2000; Xu et al., 2001). Kim et al. have shown that the 
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loss of FRK results in an increase of detectable DNA damage and impaired double stranded break 
(DSB) repair in MCF10a (Kim et al., 2015). They also noted that increased FRK expression 
correlated with increased BRCA1. Again, similar deletion constructs of FRK SH3 and SH2 
domains were generated to identify the important domain for interaction with BRCA1. The 
interaction was no capable of forming when lacking the SH3 domain which means that domain is 
key for this interaction. And much like PTEN FRK was observed phosphorylating tyrosine 1152 
of BRCA1 which enhances its stability through reduced interaction with UBE2T, which is a 
ubiquitin ligase (Kim et al., 2015). 
1.4.6 Mouse Models: 
A number of studies have been conducted where FRK has been knocked out using mouse models. 
FRK may function as a tumor suppressor however; its functions may overlap with another tyrosine 
kinase as frk-null mice are viable and display no histological abnormalities in epithelial tissues. 
Decreased levels of T3 hormone were seen but the significance of this is not understood. The frk-
null mice were monitored for two years and did not form spontaneous tumors or altered response 
to ionizing radiation (Chandrasekharan et al., 2002).  
A model addressing FRKs tumor suppressing function was generated using the MCF-10a cell line 
which is a normal breast epithelial cell line (Yim et al., 2009). MCF10a cells express FRK so the 
experiment was designed with the parental cell line as the control and an FRK knock down cell 
line. The parental cell line was unable to form tumors but, when FRK had been knocked down 
using a shRNA, tumors were able to form (Yim et al., 2009). 
1.5 Cancer-associated mutations in BFK family members, BRK and FRK: 
The BFK family member BRK has been studied extensively, and in 2015 a series of cancer 
associated mutants were analyzed for their effect on activity, signaling, cell proliferation and 
migration and substrate recognition (Tsui and Miller, 2015). Of the six mutants analyzed one was 
located in the SH3 domain (L16F), one was located in the SH2 domain (R131L), three were located 
in the kinase domain (V253M, N317S, L343F), and one was located in the C terminal tail (P450L). 
Of these BRK mutants, L16F, R131L, L343F and P450L all displayed increased enzymatic activity 
compared to wildtype BRK activity. This study revealed that a number of cancer associated 
mutants varyingly effect the kinase activity of BRK. This altered activity also affects BRK 
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regulated processes, which result in atypical substrate recognition, cell proliferation, migration, 
and invasion (Tsui and Miller, 2015). Like BRK, cancer associated mutations have also been 
identified in FRK with implications not only on FRK enzymatic activity but also its cellular 
functions. Pilati et al. identified FRK gain-of-function mutations, all of which were found in the 
FRK kinase domain (Table 1). Similarly, we found that certain residues in FRK were conserved 
with those found to be mutated in BRK in patient cancer tissues. It is therefore likely that these 
residues are also functionally conserved and important to study in the context of FRK enzymatic 
activity and FRK cellular functions. Unique cancer associated mutations of FRK will also be 
analyzed, those being R64P, K87N, S145R, K265R, N359I, and VF. 
A SRMS null mouse model has also been generated to uncover the physiological importance of 
SRMS (Kohmura et al., 1994). Kohmura et al. determined that the SRMS knockout mice were 
viable and fertile. No obvious abnormalities were found (Kohmura et al., 1994). 
1.6 Cell Signaling 
1.6.1Mitogen Activated Protein Kinases (MAP Kinases) 
MAP kinases are a family of serine/threonine kinases which control signaling pathways that 
transduce extracellular signals including response to hormones, or activation of signaling receptor 
kinases (Pearson et al., 2001). MAP kinases are divided into three levels (MAP3K, MAPKK, and, 
MAPK) which is held together to important cellular organelles through the use of scaffold proteins 
(Pimienta and Pascual, 2007). The MAP3K are activated at the cell membrane then function to 
phosphorylate MAPKK which phosphorylate MAPKs which then are capable of entering the 
nucleus to alter gene transcription depending on the initial signal (Pimienta and Pascual, 2007). 
The first well studied MAP kinase pathway was the Ras-Raf pathway which is important for 
cellular functions such as differentiation and cell proliferation, however, if left unregulated this 
pathway can provide growth signals to cancer cells (Avruch et al., 2001). The Ras protein is a 
guanosine triphosphatase (GTPase) which binds both GDP and GTP and has low intrinsic GTP 
hydrolysis (Wennerberg et al., 2005). Guanine nucleotide exchange factors (GEF) replace the GDP 
within RAS to GTP for RAS to become fully active. This GTPase is localized to the membrane 
where it can respond and transduce a variety of extracellular signals to downstream effectors 
(Wennerberg et al., 2005). Ras is activated after receptor tyrosine kinases have interacted with a 
16 
 
ligand which results in dimerization and auto and transphosphorylation. These phosphorylation 
events allow GEFs to bind through their SH2 domains and activate RAS. Ras then recruits PI3K 
which in turn activates AKT leading to a series of cell signaling events that lead to cell survival 
through MAP kinases (Mor and Philips, 2006).  
1.6.2 Signal Transducer and Activator of Transcription 3 (STAT3) Pathway: 
Signal transducer and activator of transcription (STAT) are a group of proteins which play roles 
as signaling proteins as well as transcription factors and have implications in cancer progression 
(Yu and Jove, 2004). This family of proteins is made up of seven members: STAT1-4, STAT5a-
5b, and STAT6. The STAT proteins work in tandem with Janus kinases (JAK) where JAKs 
become activated through interaction with an activated membrane receptor and dimerization/ 
transphosphorylation occurs (Rawlings et al., 2004). The activated JAKs then phosphorylate 
STAT proteins which then translocate to the nucleus to alter gene transcription (Rawlings et al., 
2004).  
STAT3 activation can occur through interleukin-6 (IL6), JAKs as described above or through 
interactions with Src kinases (Subramaniam et al., 2013).The activation of STAT3 lead to the 
activation of genes associated with increased cell proliferation, cell survival, invasion, 
angiogenesis and metastasis (Al Zaid Siddiquee and Turkson, 2008). STAT 3 is phosphorylated 
and activated at two sites, tyrosine 705 and serine 727. The activation site of STAT3 tyrosine 705 
is phosphorylated through the JAKs and the kinases that phosphorylate serine 727 have yet to be 
determined. The phosphorylation of tyrosine 705 has been associated with poor prognosis and poor 
overall survival in pancreatic ductal carcinoma (Denley et al., 2013).  
1.6.3 c-Jun and c-Jun N Terminal kinases (JNKs): 
c-Jun is transcription factor found in the nucleus who play a role in cell proliferation, and apoptosis 
(Leppa and Bohmann, 1999). This transcription factor has been shown to have effects on cell 
proliferation in chicken embryo fibroblasts where the overexpression of c-Jun and also that 
removing the first 27 amino acids towards the N-terminus of c-Jun further activate its oncogenic 
potential (Bos et al., 1990). Post translational modifications activate c-Jun with phosphorylation 
sites on serine 63 and 73. c-Jun N terminal kinases (JNKs) which are thought to play roles in 
inflammation, cell differentiation and apoptosis, are responsible for phosphorylating these serine 
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residues and activating c-Jun (Karin, 1995; Weston and Davis, 2002). JNKs, also have been found 
to have an impact on cell migration and invasion in human adenocarcinomas (Hauck et al., 2001).A 
study performed in 2012 by Zhou et al. revealed the relationship between JNK/ c-Jun and FRK in 
glioblastoma (Zhou et al., 2012). FRK is lost in high grade glioblastoma, however the 
reintroduction of FRK resulted in reduced signaling through JNK/ c-Jun and reduced migration 
and proliferation (Zhou et al., 2012). 
1.6.4 PI3K/ AKT Signaling: 
Phosphoinositide 3-kinases (PI3Ks) are a group of lipid bound enzymes activated through EGFR 
pathways and are capable of phosphorylating 3’ OH of phosphoinositol to phosphatidylinositol 3, 
4, 5-triphosphate (PIP3) in response to extracellular signals (Kaplan et al., 1987). Phosphorylation 
of PIP3 results in a cellular message that impacts cell growth, cell survival, and cell proliferation 
but this phosphorylation event can be reversed by PTEN (Bader et al., 2005; Maehama and Dixon, 
1998). AKT is a protein kinase that is responsible for mediation of signals from the second 
messenger PIP3 and generally found to be hyper active in tumors (Cantley, 2002). PIP3 allows for 
AKT to bind through its pleckstrin homology domain (PH domain) localizing to the membrane  
where it can interact with its many substrates that result in cell proliferation, and cell survival 
(Manning and Cantley, 2007). 
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Table 1 
FRK cancer associated mutations found utilizing cBioPortal. Mutations listed include nonsense, 
frameshift, in-frame deletion, in-frame deletion+insertion and missense mutations. Some of 
these include activating FRK mutants in liver cancer (20-31) (Goel and Lukong, 2016). 
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2.0 Rationale  
BRK and FRK exhibit nearly 45% amino acid sequence homology. A recent study identified key 
amino acid residues in the BRK SH3, SH2, and the kinase domain which were found mutated in 
various cancer types (Tsui and Miller, 2015). These mutations were found to alter the enzymatic 
activity of BRK (Tsui and Miller, 2015). Interestingly we noted that several of these amino acid 
residues are conserved in FRK (Table 2).  
Table 2.1 
Cancer-related BRK mutations studied by Tsui and Miller. The type of cancer each mutant is 
associated with is presented and the similar amino acid in FRK. 
Mutant 
no. 
Mutation in 
BRK 
Cancer Type Similar 
residues in 
FRK 
1 L16F Clear cell renal cell carcinoma L50 
2 R131L Gastric cancer R169 
3 V253M 
Head and neck squamous cell 
carcinoma V295 
4 N317S Ovarian Carcinoma N359 
5 L343F Cutaneous squamous cell carcinoma 
Not conserved 
(E388) 
6 P450L Pancreatic cancer 
Not conserved 
(A500) 
 
Table 2.2  
Cancer-related FRK mutations presented with the cancer they were identified in. 
Mutant 
no. 
Mutation in 
FRK 
Cancer Type 
1 R64P Breast Cancer 
2 K87N Large Intestine Cancer 
3 S145R Ovarian Cancer 
4 K265R Breast Cancer 
5 N359I Liver Cancer 
6 del VF Liver Cancer 
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3.0 Hypothesis 
We hypothesize that mutating these conserved amino acid residues in FRK (Table 2) would alter 
the enzymatic activity of FRK in a manner similar to that observed in BRK. Given that FRK plays 
a tumor suppressor role in breast cancer, we further hypothesize that FRK cancer-associated 
mutations (Table 2.2) would alter the growth-inhibitory functions of FRK in a kinase-dependent 
manner.   
3.1 Objectives 
We propose to investigate the following specific objectives: 
1. To generate point mutations in FRK and assess the effect of these mutations on FRK kinase 
activity.    
2. To examine the effect of specific FRK SH3 and SH2 mutations on intramolecular and 
intermolecular interactions.   
3. To assess the effect of these mutations on FRK-regulated signaling pathways JAK/STAT, 
AKT, and JNK/c-Jun pathways.   
4. To study the effect of these mutations on FRK-regulated growth inhibition in breast cancer and 
liver cancer cells.   
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4.0 Materials and Methods 
4.1 List of Reagents 
Table 4.1.1 
All Materials used. 
Name Manufacturer 
Catalogue 
Number 
Acrylamide Sigma A5934 
Acetic Acid Fisher A465250 
Agar Fisher BP1425-2 
Agarose Fisher BP1360 
Ammonium Persulfate (APS) Sigma A3678 
Ampicilin Amresco 0339-25g 
Aprotinin Sigma A6279-10 mL 
Bisacrylamide N'N-methylene Amresco 172 
Bovine Calf Serum Thermo Scientific SH30087.02 
Chloramphenicol Fisher Bp904-100 
Coomassie stain Biorad 161-0406 
Disodium Phosphate (NA2HPO4) Fisher S375-500 
Dimethyl Sulfoxide (DMSO) Fisher TS-20684 
DTT Fisher Bp172-25 
Dulbecco's Modified Eagle Medium 
(DMEM) Thermo Scientific SH30023.01 
EDTA Fisher Bp120-500 
Fetal Bovine Serum Fisher 10437028 
GST Binding Resin Novagen 70541-3 
Gel Red Biotium 41002 
Glycerol Sigma G5516 
Glycine Fisher S80028 
Hydrochloric Acid (HCl) Fisher A508-P500 
IPTG Bioshop IPT001.10 
Kanamycin Millipore 420311 
LB Media Fisher Bp1426-2 
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Name Manufacturer 
Catalogue 
Number 
Laemmli 2X Sigma 1001698428 
Methanol Millipore MX0475 
Monopotassium Phosphate (KH2PO4) Fisher BP-362-500 
NaCl Amresco 0241-5kg 
Nitrocellulose Membrane Pall Life 66489 
Phusion Polymerase Thermo Scientific F-530S 
Potassium Chloride Fisher AC193780000 
Polyethyleneimine (PEI) Sigma 408727 
Phenylmethylsulfonylfluoride (PMSF) Omnipur 711OCN 
Sodium Dodecyl Sulfate (SDS) Sigma L3771 
Skim Milk BD Difco  DF0032173 
TEMED Amresco 0761-CA-100 mL 
Tris Base Fisher Bp152-5 
Triton 100X Sigma T8787-100 mL 
Tween Fisher BP337500 
 
 
4.2 Identification of Cancer-Associated Mutations 
4.2.1 Catalogue of Somatic Mutations in Cancer 
All cancer associated mutations were found using COSMIC (Catalogue of Somatic Mutations in 
Cancer). COSMIC labels all mutations known onto a schematic of the protein where they can be 
selected in order to present information about the mutation. The information includes the tissue 
type the mutation is associated with, the number of times the mutation has been observed  and 
patient information. 
4.2.2 Mutation Criteria 
158 mutations can currently be found for FRK on COSMIC so, in order to select a reasonable 
number of mutations for study we needed a criteria to avoid selecting mutations that would either 
have no effect on the functionality of FRK and such that we can hypothesize the reason for 
malfunction of FRK. The first requirment for mutations was that at least one mutation should be 
found in each functional domain. Secondly, mutations should be associated with breast cancer or 
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liver cancer as FRK has been shown to function as a candidate tumor suppressor in breast cancer 
and to have possible oncogenic function in liver cancer. Several muations selected occur in breast 
cancer or liver cancer, those being R64P, and K265R in breast cancer and N359I, and VF in liver 
cancer. Third, mutations that occur in coinserved motifs or adjacent to critical amino acids should 
be selected. Select mutations were found in conserved motifs or near critical residues, those being, 
S145R found in the phosphotyrosine binding pocket, N359I found in the DLAARN motif and 
K265R which is near the ATP contacting lysine K262. Lastly we selected mutations which have 
occurred more than once, those being K87N which has been seen twice, and N359I which has been 
seen three times. 
  
4.2.3 Multiple Sequence Alignment 
A multiple sequence alignment was performed by uploading sequences to Clustal omega in order 
to observe conserved regions and critical residues between FRK, BRK and SRMS. This was 
important for determining hypotheses for how certain mutations function.  
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Figure 4.2 1 
Multiple Sequence Alignment of FRK, BRK, SRMS, and Src. Red residues indicate FRK cancer-
associated mutations. Green amino acids indicate cancer-associated mutations of BRK and 
conserved residues in FRK. Yellow highlighted residues indicate conserved regions between all 
proteins. SH3 (yellow), SH2 (green), and kinase (blue) domains are underlined and labelled. 
 
SH3 
SH2 
Kinase 
25 
 
4.3.0 Site Directed Mutagenesis 
 
All PCR amplifications were performed using the Phusion polymerase (F-530S, ThermoFisher 
Inc, USA) supplied as a mastermix, using the manufacturer’s instructions, as appended below: 
PCR using Phusion Polymerase: 
25 L Phusion master mix, 1L forward primer (10 M), 1 L reverse primer (10M), 1 L 
DMSO, 22 L H2O. 
Cycling conditions: 
1. Initial Denaturation                            98 C (30 seconds) 
2. Extension (30 cycles)                         98 C (10 seconds) 
                                                            3 C above primer melting temperatures (1 minute) 
                                                            72C (4 minutes) 
3. Final Extension                                   72C (5 minutes) 
All mutants were transformed into the XL Gold E. coli cell line. 
4.3.1 Primer Design 
Primers were designed by analyzing the DNA sequence surrounding the point mutation. The codon 
of interest was exchanged for the codon of the specific mutation. 15 nucleotides on either side of 
the mutation were added to the primer to give the primer a length of 33 nucleotides.4.3.2 Primers 
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Table 4.3.2  
All primers used. All written 5`-3`. 
Mutation Direction Sequence 
BRK L16F Forward CCCAAGTATGTGGGCTTTTGGGACTTCAAGTCC 
Reverse GGACTTGAAGTCCCAAAAGCCCACATACTTGGG 
BRK R131L Forward CACTACAAGATCTGGCTTCGTGCCGGGGGCCGG 
Reverse CCGGCCCCCGGCACGAAGCCAGATCTTGTAGTG 
BRK 
V253M 
Forward CTGGCGCTGTACGCCATGGTGTCCGTGGGGGAC 
Reverse GTCCCCCACGGACACCATGGCCTACAGCGCCAG 
BRK N317S Forward GACCTGGCCGCCAGGTCTATCCTCGTCGGGGAA 
Reverse TTCCCCGACGAGGATAGACCTGGCGGCCAGGTC 
BRK L343F Forward AAGGAGGACGTCTACTTTTCCCATGACCACAAT 
Reverse ATTGTGGTCATGGGAAAAGTAGACGTCCTCCTT 
BRK P450L Forward ACCAGCTACGAGAACCTTACCTGA 
Reverse TCAGGTAAGGTTCTCGTAGCTGGT 
 
FRK L50F Forward CACTACTTTGTGGCTTTTTTTGATTACCAGGCT 
Reverse AGCCTGGTAAAAAAAAGCCACAAAGTAGTG 
FRK R169L Forward CACTACAGAATTAAACTACTGGATGAAGGGGGA 
Reverse TCCCCCTTCATCCAGTAGTTTAATTCTGTAGTG 
FRK 
V295M 
Forward ATCCAGCTTTATGCTATGTGCACTTTAGAAGAT 
Reverse ATCTTCTAAAGTGCACATAGCATAAAGCTGGAT 
FRK N359I Forward GATCTGGCTGCCAGAATTGTCCTCGTTGGTGAA 
Reverse TTCACCGAGGACAATTCTGGCAGCCAGATC 
FRK E388I Forward AATGAAGACATCTATATTTCTAGACACGAAATA 
Reverse TATTTCGTGTCTAGATAAATAGATGTCTTCATT 
FRK 
A500W 
Forward TCTTCATATTCAGATTGGAATAACTTCATAAGA 
Reverse TCTTATGAAGTTATTACCATCTGAATATGAAGA 
FRK R64P Forward GAGGACTTGAGCTTCCCTGCAGGTGACAAACTT 
Reverse AAGTTTGTCACCTGCAGGGAAGCTCAAGTCCTC 
FRK K87N Forward GCCAGACACTTGGAGAATAGACGAGATGGCTCC 
Reverse GGAGCCATCTCGTCTATTCTCCAAGTGTCTGGC 
FRK K265R Forward GCAGTGAAAACATTACGTCCAGGTTCAATGGAT 
Reverse ATCCATTGAACCTGGACGTAATGTTTTCACTGC 
FRK VF Forward TTTGGACTTGCCAGAAAGGTAGATAATGAA 
Reverse TTCATTATCTACCTTTTCTGGCAAGTCCAAA 
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4.4 Transformation 
The PCR product was treated with 1 L of Dpn I overnight in order to degrade the parental 
plasmid. Competent XL Gold cells were used for the transformation which were thawed for 15 
minutes. Then 5 L of the PCR product was added to 50 L of the competent cells. This was 
allowed in incubate on ice for 30 minutes. The cells were heat shocked at 42oC for 1 min and 
placed back on ice for four minutes. 300 L of antibiotic free media was added and was incubated 
at 37oC in a shaker for one hour. The cells were then centrifuged at 1000 x g for 1 min and 
resuspended in 80 L of antibiotic free media. The entire contents were then spread on an agar 
plate with appropriate antibiotic drug and incubated for 12 – 16 hours. Colonies were picked using 
pipette tips and grown in 5 mL cultures with the appropriate antibiotic for 12 hours. 
4.4.1 DNA Isolation for Transformation (Mini/ Maxi Prep) 
4.4.1.1 Mini Prep: Small Scale DNA Isolation  
1.5 mL of culture was taken and centrifuged at 5000 x g for one minute. The cell pellet was 
resuspended in 110 L of P1 buffer (Qiagen). Once resuspended, 100 L of P2 lysis buffer 
(Qiagen) was added and incubated for four minutes at room temperature. Immediately after the 
four-minute incubation, 120 L of P3 neutralization buffer (Qiagen) was added and the tubes were 
shaken vigorously until a white precipitate had formed. This was centrifuged at 17000 x g for 10 
minutes and the supernatant was transferred to a new tube where the DNA was precipitated with 
200 L of cold isopropanol. The DNA was centrifuged at 17000 x g for one minute and the 
supernatant removed. 500 L of 70% ethanol was added to the DNA pellet and centrifuged at 
17000 x g for one minute. The ethanol was poured off and the DNA was centrifuged at 17000 x g 
for one minute. At which point the remaining ethanol was removed using a pipette and the DNA 
pellet was allowed to air dry for 15 minutes. Once dry the DNA pellet was resuspended with 30 
L of ddH20 and quantified using nanodrop. DNA from this process was used mainly for 
transformation. 
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4.4.1.2. Maxi Prep:  
500 mL of starter culture was added to 400 mL of media with appropriated antibiotic and incubated 
for 12-16 hours. The culture was centrifuged at 5000 x g for 10 minutes and the pellet was 
resuspended in 10 mL of P1 buffer (Qiagen). 10 mL of P2 lysis buffer (Qiagen) was added and 
incubated for four minutes, at which point 10 mL of P3 neutralization buffer was added and shaken 
until a white precipitate had formed. This then incubated on ice for 20 minutes and was then 
centrifuged at 20000 x g for 30 minutes. DNA binding column Qiagen-tip 500 (Qiagen) was 
equilibrated with 10 mL of QBT buffer (Qiagen) and allowed to empty by gravity flow. The 
supernatant containing plasmid DNA was then added to the column and emptied through gravity 
flow. The column was then washed with 2 times with 30 mL of QC buffer (Qiagen). DNA was 
then eluted with 15 mL of QF buffer (Qiagen) into a tube containing 10.5 mL of cold isopropanol. 
Precipitated DNA was then centrifuged at 17000 x g for 10 minutes and the supernatant discarded. 
DNA pellet was then washed using 5 mL of 70% ethanol and centrifuged at 17000 x g for 10 
minutes. Supernatant was removed again, and the DNA pellet was centrifuged at 17000 x g for an 
additional 10 minutes. DNA was allowed to air dry for 15 minutes where it was resuspended in 
300 L of TE buffer and quantified using nanodrop. DNA from this process was used mainly for 
transfection. 
4.4.2 DNA Sequencing:  
DNA to be sequenced was diluted to 100 ng/ mL in a 10 L volume and primers located 400-500 
bp upstream of were diluted to 50 M in a 50 L volume. Sanger sequencing was performed at 
the NRC and analysis was performed utilizing pDraw software. 
4.5 Cell Culture:  
All cell lines were maintained in high glucose (4.5 g/L) Dulbecco’s modified eagle media 
(DMEM) with 10% bovine calf serum (BCS). Wastes comprising of cells, trypsin and other 
components was disposed of with 30% bleach and sent in double sealed bags for autoclaving and 
were further disposed of. All working utensils and latex gloves were decontaminated with a 
thorough spraying of 70% ethanol before use.  
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4.5.1Cell Lines Used:  
Cell lines used included, HEK293, MDA-MB-231, and HEP3B. HEK293 and HEP3B were 
supplemented with 10% bovine calf serum, where MDA-MB-231 was supplemented with 10% 
fetal bovine serum (FBS).  
4.5.2 Plasmids Used: 
Plasmids used were pE-GFP for transient transfection, LPC for stable cell line generation, and 
PRL-652 for bacterial protein expression. 
4.6 Transfection 
HEK 293 cells were transfected when the plate was 70% full at which point 2.5 g of DNA was 
combined with 110 L and of 150 mM NaCl. 15 L of 1% PEI (polyethylene imine) (Sigma 
Aldrich) was added and incubated for 10 minutes at room temperature. The entire contents were 
then added dropwise to the cells. Cells were allowed to incubate for 24 hours and were assessed 
for fluorescence. 
4.6.1Cell Lysate Preparation: 
Cells after transfection or from stable cell lines were lysed around 90-95% confluent in six-well 
plates. Media was removed from wells and 200 L of 2X laemmli buffer was added to each well. 
The cells and buffer were scraped until the entire well had been covered and the buffer had become 
viscous. Buffer and cells were then pipetted into a new tube and were boiled at 100oC for 5 minutes. 
 
4.7 Western Blotting  
The transfection efficiency was estimated 24 hours after transfection. Cells were then lysed in 200 
L of 2X Laemmli. The samples were boiled for 5 minutes and 5 L was loaded on a 10% 
polyacrylamide gel. The gel was resolved for 1 hour at 100V. All proteins were transferred to a 
membrane by pressing the gel to the membrane in between sheets of filter paper and resolved for 
1.5 hours at 100V. The membrane was blocked for 40 minutes with skim milk (5%). Following 
blocking, the primary antibody (anti phospho- tyrosine, and anti GFP, 1:1000) was added and 
incubated on a shaker at C overnight. The membrane was washed 3 times with 1X PBST for 5 
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minutes. Secondary antibody solution was added to the membrane and incubated at 1.5 hours at 
room temperature. The membrane was washed with PBST, similarly to the previously stated 
method. Antibodies that bound the GST fusion protein were visualized on licor.        
4.8 Stable Cell Line Generation 
The amphotrophic HEK 293T cell line was utilized for generation of FRK containing retrovirus. 
The FRK LPC vector was transfected into the amphotrophic cell line when the cells covered 70% 
of the plate at which point 12.5 g of DNA was combined with 550 L of 150 mM NaCl and 15 
L of 1% PEI (polyethylene imine) and incubated for 10 minutes at room temperature. The entire 
contents were then added dropwise to the cells. The virus is released into the media and harvested 
24 and 48 hours after transfection. Each collected volume of virus is used to transduce MDA-MB-
23. Puromycin was then added at a concentration of 2.5 g/ mL to select for transduced cells. 
Selection continued until colonies had formed. Polyclonal populations were selected for further 
experimentation. 
4.9 Cloning 
4.9.1.   Cloning into pRL-652  
Mutagenesis was performed as previously described in section 4.2 on existing FRK WT SH3 and 
SH3 domains in the PRL-652 vector 
4.9.2Cloning into LPC vector 
Mutagenesis was performed as previously described section 4.2 on existing FRK WT full length 
DNA in the LPC vector.  
4.10 Polyacrylamide Gel: 
Resolving gel: Acrylamide (10%), Tris pH 8.8 (375 mM), SDS (0.1%), APS (0.1%), TEMED 
(0.01%), H2O up to 8 mL. 
Stacking gel: Acrylamide (6%), Tris pH 6.8 (125 mM), SDS (0.1%), APS (0.1%), TEMED 
(0.01%). 
Both gels were allowed to solidify for 15 to 20 minutes before proceeding. 
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4.11 Migration Assay 
Cell migration was analyzed using a wound healing assay. Approximately 200 000 cells were 
added to each well of a 12 well plate and allowed to incubate for 12 hours. Once all the cells had 
adhered to the surface, a 200 L pipette tip was used create a wound down the center of the plate. 
The closure of each wound was monitored every 12 hours by measuring the area within the wound 
using imageJ. The cells were monitored for three days to assess the closure of the wound. 
4.12 Proliferation Assay 
Cell proliferation was analyzed by measuring mitochondrial viability using Cell Counting Kit-8 
(CCK-8) (Dojindo, CK04-05). The CCK8 compound was reduced by mitochondrial 
dehydrogenases. This reduction causes the compound to change colour based on the number of 
viable cells present. 1000 stable cells were seeded in 96-well plates and cultured in 100 μL culture 
medium (1000 cells/well). The cell proliferation assay was performed for 5 days. 10 μL of CCK-
8 solution was added to each well, and then the cells were incubated for 2 hours at 37C. Following 
treatment with CCK-8, absorbance was read at 450 nM.  
4.13 Invasion Assay 
Cell invasion assay was performed using EMD Millipore Boyden chambers including a 
polycarbonate 8.0 m pore size coated with extracellular matrix (EMD Millipore ECM550) 
following the manufacturer’s instructions with slight modifications. Boyden chambers were 
allowed to reach room temperature and 200 L of DMEM media lacking FBS was added for two 
hours to rehydrate the membrane. Cells were counted and resuspended (2x105 cells/ well) in serum 
free media and added to the inserts. Each insert was placed in a well of a 24 well plate containing 
500 L of 10% FBS DMEM media and incubated for two days at C. Following incubation, the 
media on the interior of the chamber was removed and the insert was placed in 500 L of trypan 
blue stain for 20 minutes. Excess dye was removed, and cells were counted. 
4.14 Rotational Anisotropy 
Rotational anisotropy was used the measure the binding affinity of the SH3 and SH2 domains and 
their mutants to fluorocein labeled peptides. The reactions were 60 L and contained a fluorocein 
labeled peptide at a concentration of 50 nM in buffer (1 mM DTT, 50 mM Tris, 150 mM NaCl) 
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and the FRK domain was titrated in at varying concentrations depending on the experiment until 
saturation occurred. The equipment used to collect data and calculate anisotropy was a 
QuantaMaster QM-4 spectrofluorometer (Photon Technology International) with a dual emission 
channel. The samples were excited with vertically polarized light at 495 nm and vertical and 
horizontal emissions were measured at 520 nm. Dissociation constants (Kd) were found by fitting 
a sigmoidal curve using sigma plot software.  
4.14.1 Protein Purification 
E.coli containing the bacterial expression vector with the FRK mutants were grown in a 5 mL 
culture with 5 g/ mL ampicillin. The culture was grown for 12-16 hours and then transferred to 
1 L of LB media and grown for 3-5 hours or until the OD600
 = 0.6-0.8 (optical density at 600 nm). 
Protein expression was then induced with 1 mM (final concentration) IPTG and the culture was 
incubated at 15oC for an additional 16 hours. Cultures were then centrifuged at 5000 x g and 
resuspended in 20 mL of lysis buffer (1 mM DTT, 50 mM Tris, 150 mM NaCl, 1% Triton, PMSF 
100 mM, Aprotinin 2 mM). The bacterial resuspension was then lysed through sonication using 
one second bursts, ten times, and for 5 rounds. Cell lysate was centrifuged at 20000 x g for 30 
minutes and supernatant was incubated overnight at 4oC on GST binding resin (Novagen, 70541) 
which had been equilibrated with three 5 mL washes of buffer (1 mM DTT, 50 mM Tris, 150 mM 
NaCl). Three 5 mL washes with buffer were done to remove any protein bound non-specifically. 
All GST-FRK constructs were eluted from the column using buffer with 20 mM glutathione plus 
10% glycerol and aliquoted into 1 mL volumes. Each volume was then visualized via coomassie 
and quantified using Bradford test.  
 
4.15 Statistics  
All statistics performed were student t-tests, using the functionality of Excel. 
5.0 Results 
FRK and BRK mutations were generated via site directed mutagenesis and confirmed through 
DNA sequencing. All constructs were cloned into the pE-GFP vector to assess phospho tyrosine 
activity via transient expression. Mutations within the SH3 and SH2 domains (R64P, K87N, and 
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S145R) were cloned into the pRL-652 vector for expression in E. coli cells to assess the effects on 
binding. FRK constructs N359I, VF, R64P and K265R were cloned into the LPC vector designed 
for stable cell line generation. The activity of each construct was observed through transfection 
into HEK 293 cells and western blotting with anti-phosphotyrosine and anti-GFP antibodies. 
Mutations selected from breast cancer and liver cancer were stably expressed in MDA-MB-231 
cells and anti-proliferative effects were assessed using proliferation, CCK8; migration, wound 
healing; and invasion assays, Boyden chambers. 
5.1 Effect of Similar FRK Mutations on Enzyme Activity 
A previous study on BRK (Tsui and Miller, 2015) characterized six cancer related mutations in 
BRK and it was found that these residues were similar in FRK or found adjacent to the 
autophosphorylation site and C-terminal regulatory tyrosine. Through the transient expression of 
these constructs from FRK and BRK in HEK 293 cells we observed that these conserved residues 
have differing functions in FRK (Figure 5.2). 
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Figure 5.1 
(Left) HEK 293 cells were transfected and transiently expressing BRK cancer related mutations. 
Global phospho-tyrosine activity analyzed through western blot utilizing phospho-tyrosine and 
GFP Antibodies. (Right) Transient Expression of mutated FRK residues that are similar to the BRK 
cancer-related mutations in HEK 293 cells. Global phospho-tyrosine activity analyzed through 
western blot utilizing phospho-tyrosine and GFP Antibodies 
 
The cancer related mutations of BRK displayed varying effects on activity. Several mutations 
enhanced the kinase activity which include L16F and P450, whereas R131L, V253M, N317S and 
L343F revealed a reduction in kinase activity. When analyzing the mutation of conserved residues 
in FRK we found that these mutations exhibited differential phosphorylation compared to the 
cancer related mutations in BRK (Figure 5.2). All FRK mutations maintained the kinase activity 
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comparable to the wild type protein except for V295M and N359I which show reduced and 
abolished activity, respectively.  
5.2 Effect of Cancer-Related FRK Mutations on Activity 
A number of cancer related mutations in FRK have been catalogued in a series of databases and 
several mutations were chosen to analyze more in depth. All mutants were examined through 
western blot techniques and compared to wild type FRK which displays upregulated kinase 
activity. The mutations chosen for further study include R64P (Breast cancer), K87N (Large 
intestine cancer), S145R (Ovarian cancer), K265R (Breast cancer), N359I (Liver cancer), V378-
F379 del (VF) (Liver cancer) and V378-K380 del (Liver cancer). The VF mutation was identified 
in a previous study (Pilati et al., 2014). The SH3 domain mutations (R64P, K87N) and the SH2 
domain mutation (S145R) all showed kinase activity similar to wild type. The kinase mutation VF 
(V387-F379 del) showed elevated kinase activity. K262R exhibited reduced kinase activity and 
N359I abolished kinase activity (Figure 5.2.1). These were seen as statistically significant through 
the quantification of all activities as presented in figure 5.2.2. 
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Figure 5.2.1  
Transient Expression of cancer related FRK mutations in HEK 293 cells. Global phospho-tyrosine 
activity analyzed through western blot utilizing phospho-tyrosine and GFP Antibodies. 
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Figure 5.2.2  
Kinase activity of each mutation relative to the kinase activity of wild type FRK. With significant 
differences being indicated by *. K265R, and N359I exhibit reduced kinase activity and VF shows 
elevated kinase activity. 
5.3 Visualization of Cancer-Associated Mutations Located in Conserved Motifs 
In order to interpret the change of level of kinase activity we used a SRC crystal structure to 
analyze the importance of mutations S145R and N359I using PyMOL software. Src was used 
because of readily available crystal structures where the conserved motifs could be viewed. The 
reason we were only able to analyze these two mutants is because these were the only mutations 
located in highly conserved motifs and the structure of FRK has not yet been solved. The first of 
the two mutations is the S145R mutant which lies in the phospho-tyrosine binding site within the 
SH2 domain. This specific serine residue has also been noted to be involved in phospho-tyrosine 
binding in the Abl kinase. Also the mutation of this serine in Abl kinase resulted in lost phospho-
tyrosine binding (Mayer et al., 1992). We therefore expected that this mutation would disrupt the 
self-regulation of FRK and result in increased activity. 
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Figure 5.3.1  
Mutation of S145R (FRK) shown using a SRC SH2 crystal structure 4F5B. A) The entire SRC 
SH2 domain crystal structure. B) Close up of the serine 180 (Blue) (SRC) exhibiting the hydrogen 
bonding of S180. C) Serine 180 (SRC) mutated to arginine mimicking the S145 in FRK  
 
5.3.1: S145R FRK SH2 Domain 
This model shows the serine interacting directly with the phospho-tyrosine as well as the backbone 
of residues 182 and 183 (Figure 5.3.1). Mutating this residue to an arginine results in a number of 
different rotamers and the most frequently occurring rotamer results in lost binding to the 
phosphor-tyrosine and lost interactions with the neighbouring residues. Mutating this serine 
residue in the SH2 phospho-tyrosine binding sequence should result in the lost self-regulation of 
FRK as well as increased kinase activity. 
5.3.2: N359I FRK Kinase Domain 
The second mutation visualized the (N359I) lies in the activation loop of FRK. This mutation lies 
in a motif is highly conserved and is found most often in NRTKs.  
A 
B C 
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Figure 5.3.2  
Mutation of N359I (FRK) shown using a SRC crystal structure 2SRC. A) Complete SRC crystal 
structure complexed with ANP-PNP (ATP analogue). B)  Close up of N394 (Blue) (SRC) 
exhibiting the hydrogen bonding of N394. C)  N394 (SRC) mutated to isoleucine mimicking the 
N359I (FRK). 
 In Figure 5.4.2, the wild type asparagine appears to be interacting with both the ATP molecule as 
well as aspartate 386. Aspartate 386 is known as the catalytic base that is required for the proper 
function of the kinase. This aspartate residue has been shown to deprotonate the tyrosine of the 
target protein (Cheng et al., 2010). Mutating the asparagine 386 residue to isoleucine in SRC 
disrupts the interaction with both the aspartate 386 and the ATP molecule. Loss of these 
interactions should cause decreased kinase activity due to improper ATP positioning or because 
aspartate 386 is no longer positioned to deprotonate the target tyrosine.  
 
5.4 Effect of Cancer-Associated Mutations on Cell Proliferation 
FRK has been previously shown to supress proliferation in MCF7 and MDA-MB-231 breast 
cancer cells (Ogunbolude et al., 2017b; Yim et al., 2009). In order to analyze the rate of cell growth, 
stable cell lines were generated using select mutations. Of the mutations that were analyzed above, 
A 
C B 
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the two breast cancer mutations (R64P and K265R) and the two liver cancer mutations (N359I and 
VF) were stably expressed in MDA-MB-231 cells. This cell line was chosen because it shows low 
levels of FRK and is a highly metastatic and tumorigenic cell line. These qualities exhibited make 
MDA-MB-231 an ideal cell line to test the tumor suppression function of FRK.  
 
 
 
 
Figure 5.4.1 1 
Stable expression of FRK measured using western blotting and FRK antibodies. Wild type FRK 
(FRK WT), FRK R64P, FRK K265R, FRK N359I, FRK VF 
 
The control was the MDA-MB-231 cell line without exposure to the FRK containing retrovirus. 
All five constructs: FRK WT, FRK R64P, K265R, N359I, and VF showed significant expression 
of FRK after with selection with puromycin into polyclonal populations. To assess cell 
proliferation rates, we employed the CCK-8 reagent which measures dehydrogenase activity in 
active mitochondria and can be used to quantify the number of viable cells. We hypothesized that 
the mutants with higher kinase activity (Figure 5.4.1) than the wild type FRK would have more 
of a dramatic anti-proliferative effect where the R64P and VF mutants would have decreased 
proliferation, K265R and N359I would not have as drastic of an anti-proliferative effect as the 
wild type FRK.  
FRK wild type expressing cells resulted in a significantly reduced growth rate (Figure 5.5.2) 
compared the MDA-MB-231 cell line (p value < 0.05) alone which has been shown previously by 
our lab (Ogunbolude et al., 2017b). The mutations tested: R64P, K265R, N359I, VF, did not result 
in a change in cell proliferation that was significantly different than the wild type FRK. However, 
FRK 
-Actin 
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these mutations still showed a decreased proliferation rate compared to the MDA-MB-231 cell 
line (p value < 0.05). 
 
Figure 5.4.2  
Cell proliferation rates of labelled FRK MDA-MB-231 cell lines measured with the CCK-8 assay. 
Wild type FRK (FRK WT), FRK R64P, FRK K265R, FRK N359I, FRK VF. Significantly different 
growth rates are indicated by *. 
 
5.5 Cell Migration: 
Our lab has also previously shown the expression of FRK in breast cancer cell lines results in 
reduced rates of migration, so we therefore conducted similar wound healing experiments with the 
above mentioned stable cell lines (Ogunbolude et al., 2017b). A vertical scratch was made using a 
pipette tip and the closure of the wound was monitored every 8 hours (Figure 5.5.1). Again, we 
had predicted that the rate of cell migration could be predicted by the kinase activity of each of the 
mutations. This would mean that the mutations with increased kinase (R64P, VF) activity would 
exhibit a reduced migration rate compared to the wild type FRK and the mutations with reduced 
kinase activity (K265R, N359I) would exhibit increased migration rates. At the 56-hour point 
which is the time point where the control MDA-MB-231 wound had fully closed, the wild type, 
R64P, K265R, N359I and VF mutations had closed to 66%, 41%, 38%, 42%, and 53% 
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respectively. Mutations R64P, K265R, and N359I resulted in a wound closure to between 38% 
and 42% which is a statistically significant increase of migration compared to the wild type FRK 
but decrease compared to MDA-MB-231. The VF mutation resulted in migration rate that was 
slower than the other mutations but not statistically different compared to the wild type FRK. 
 
 
 
 
 
Figure 5.5.1  
Cell migration of FRK stable cell lines measured using a wound healing assay. Wild type FRK 
(FRK WT), FRK R64P, FRK K265R, FRK N359I, FRK VF 
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5.6 Cell Invasion Assay: 
To examine the effect of the cancer associated FRK mutations, a Boyden chamber coated with 
extracellular matrix was used. The data presented showed that the cell line expressing wild type 
FRK showed significantly reduced cell invasion (P<0.05; Figure 5.6.1) by 35%. The cancer 
associated mutations were found in breast and liver cancer exhibit varying degrees of activity 
compared to the wild type FRK all show similar levels of invasion to the MDA-MB-231 control 
cell line. 
 
 
 
 
 
 
 
 
Figure 5.6 
Cell invasion assay performed using Boyden chambers coated in extracellular matrix to analyze 
the invasive properties of the FRK stable cell lines. Wild type FRK (FRK WT), FRK R64P, FRK 
K265R, FRKN359I, FRK VF. 
 
5.7 FRK Mutation effect on Signaling: 
5.7.1 FRK Mutation effect on Signaling in Stable Cell Lines: 
All FRK mutant stable cell lines were lysed as described above and their effect on signaling was 
assessed via western blotting. The signaling proteins evaluated were STAT3 and pSTAT3 on 
tyrosine 705, JNK and pJNK on tyrosine 185, c-Jun and p-c-Jun on serine 63, and AKT and pAKT 
on serine 473. FRK expression was shown to decrease levels of phosphor c-Jun and JNK (Zhou et 
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al., 2012), as well as a reduction in STAT3 and AKT signaling (Ogunbolude et al., 2017). 
However, when analyzing the effect present within the stable cell lines expressing FRK WT and 
cancer associated mutations, little effect was seen on any of the signaling molecules mentioned 
above as shown in figure 5.7.1. The only effect noted was a slight reduction in phospho-c-Jun. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7.1  
Effect of FRK cancer associated mutations on critical signaling molecules. Samples analyzed 
were, MDA-MB-231 parental, FRK WT, FRK R64P, FRK K265R, FRK N359I, and FRK VF. 
Antibodies for STAT3, pSTAT3 Y705, JNK, pJNK Y185, c-Jun, p-c-Jun S63, AKT, and pAKT 
S473. 
 
5.7.2 FRK Mutation effect on Signaling in HEK293 Transient expression: 
Since there was no effect seen in the MDA-MB-231 stable cell lines, experiments were performed 
on transient expression lysates in the less mutagenic cell line HEK293. This experiment produced 
various changes in signaling pattern. First there was no change in expression level of STAT3 
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however there was great variation in the phosphorylation at the tyrosine 705 site except in the 
N359I mutation. Next while it had been previously revealed that FRK expression is capable of 
reducing pJNK and p-c-Jun levels, no statistically relevant data was found from the transient 
expression of FRK WT and mutations. There was also no change seen in AKT, p-AKT, JNK, and 
p-JNK levels (Figure 5.7.2).  
 
 
 
 
 
 
 
 
 
 
 
Figure 5.7.2.1  
Effect of FRK cancer associated mutations on critical signaling molecules. Samples analyzed 
were, HEK293 parental, FRK WT, FRK R64P, FRK K87N, FRK S145R, FRK K265R, FRK 
N359I, and FRK VF. Antibodies for STAT3, pSTAT3 Y705, JNK, pJNK Y185, c-Jun, p-c-Jun 
S63, AKT, and pAKT S473. 
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Figure 5.7.2.2 
Quantification of the HEK 293 cell signaling western blot in figure 5.7.2.1. 
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Figure 5.7.3 
FRK mutation expression an activity in MDA-MB-231 stable cell lines and transiently transfected 
in HEK293, and parental BT20 cell line. FRK expression measured with FRK antibody, 
phosphotyrosine activity measured with pY20 antibody.  Actin used as loading control. 
The activity of the FRK mutations stably expressed in MDA-MB-231 cells was also tested. We 
found that there was no activity present while FRK was expressed at detectible levels. In order to 
be sure that there was no issue with antibodies, two controls were utilized being WT FRK 
transiently expressed in HEK293 which exhibits FRK expression and activity; and BT20 lysate 
which has been shown to express FRK (Ogunbolude et al., 2017). The HEK293 transient 
transfection showed much higher expression of FRK compared to all other samples. Analyzing all 
MDA-MB-231 stable cell lines revealed that none of the FRK constructs expressed in MDA-MB-
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231 cells possess any activity. The control FRK transiently expressed exhibited the expected 
activity where the BT20 showed no activity (Figure 5.7.3). 
5.8 Rotational Anisotropy 
These experiments involve designing peptides that are likely to interact with the protein interaction 
domains of FRK and linking a fluorescent marker to them, in this case fluorocein. The fluorescent 
marker is excited with vertically polarized light and the speed of rotation is measured with the 
QuantaMaster QM-4 spectrofluorometer (Photon Technology International). The smaller 
molecule such as the peptide alone should have the fastest rotation where the peptide bound to its 
interaction domain will have a much slower rotation (Jameson and Ross, 2010). With the 
fluorescent maker attached, the light emitted by the smaller peptide will be distributed in all 
directions. The larger peptide-protein complex will emit light in line with the original excitations 
direction in this case, vertically polarized light and result in an increase in polarization compared 
to the freely rotating peptide. Anisotropy is another term for the emission of polarized light, and 
in this case has a range from +1 to -0.5 (Jameson and Ross, 2010). The anisotropy values calculated 
from the experiments performed were then normalized with the highest anisotropy value labeled 
as 100% of the peptide bound and the freely rotating peptide labeled as 0% bound.  
SH3 binding peptides were designed based on previous studies assessing interactions between 
GST-FRK, and PTEN, and BRCA1. These experiments identified the FRK domain responsible 
for interaction and the region where binding occurred on the respective protein. PXXP motifs were 
selected and peptides were designed with five amino acids on either side of the motif. SH2 peptides 
were selected from the consensus peptide determined by Zhao et al. (Zhao et al., 2013) and from 
the FRK C terminus. 
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Figure 5.8.1  
GST expression. Lysate from E. coli expressing GST alone for purposes of control. 10, 1 mL 
fractions run as well as the protein remaining on the column after elution. Protein levels shown 
through Coomassie staining and indicated by arrow.  
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Figure 5.8.2  
FRK wild type SH3 domain expression. Lysate from E. coli expressing GST-FRK SH3 WT. 10, 1 
mL fractions run as well as the protein remaining on the column after elution. Protein levels shown 
through Coomassie staining and indicated by arrow. 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.3  
FRK wild type SH2 domain expression. Lysate from E. coli expressing GST-FRK SH2 WT. 10, 1 
mL fractions run as well as the protein remaining on the column after elution. Protein levels shown 
through Coomassie staining and indicated by arrow.  
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Figure 5.8.4  
FRK S145R SH2 domain expression. Lysate from E. coli expressing GST-FRK SH2 S145R. 10, 
1 mL fractions run as well as the protein remaining on the column after elution. Protein levels 
shown through Coomassie staining and indicated by arrow. 
Peptide Sequence Interaction Protein Interaction Domain 
PNVEEPSNPEASSS PTEN SH3 
DTYLIPQIPHSHY BRCA1 SH3 
ETDSS(pY)SDANN FRK C terminus SH2 
HF(pY)ENI Consensus Peptide SH2 
Table 5.8 1 
Peptides used for rotational anisotropy. All peptides labelled with fluorocein tag. pY indicates site 
of phosphorylation.  
 
5.8.1 FRK SH3 Domain Interactions: 
The FRK WT SH3 domain was tested with the peptides at a concentration of 50 nM and the SH3 
domain at a concentration 80 M. Unfortunately, the FRK WT SH3 domain showed no association 
with PTEN and BRCA1 peptides as there was no increase in anisotropy detected (Figures 5.81.1 
and 5.8.1.2). 
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Figure 5.8.1 1 
Anisotropy data for interaction with the PTEN peptide PNVEEPSNPEASSS showing no increase 
in anisotropy indicating no binding is occurring. 
 
 
 
 
 
 
 
 
 
Figure 5.8.1 2 
Anisotropy data for interaction with the BRCA1 peptide DTYLIPQIPHSHY showing no increase 
in anisotropy indicating no binding is occurring. 
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5.8.2 FRK SH2 WT Interactions: 
5.8.2.1 FRK WT SH2 Interaction with C Terminus: 
FRK WT SH2 shows a specific binding with its own C terminus as exhibited by rotational 
anisotropy where the FRK WT SH2 was titrated into the reaction and the anisotropy values had 
increased until they plateaued indicating that all of the peptide (FRK C terminus, 
ETDSS(pY)SDANN) had been bound (Figure 5.8.2.1.1). From this the Kd value was interpreted to 
be 2.5 M as was calculated by fitting a sigmoidal curve by regression analysis. This data indicates 
that the FRK WT SH2 domain and FRK C terminus can interact with high affinity (Figure 
5.8.2.1.1). 
 
 
 
 
 
 
 
 
Figure 5.8.2.1 1 
Rotational anisotropy was used to measure the interaction between FRK WT SH2 and FRK C 
terminus. Anisotrpoy data was normalized to fraction of FRK C terminus bound and a Kd value 
was found by regression analysis by fitting a sigmoidal curve to the average of three different 
experiments. Kd vaule = 2.5 M. 
5.8.2.2 FRK WT SH2 Interaction with Consensus Peptide 
FRK WT SH2 shows a specific binding with the SH2 consensus peptide as exhibited by rotational 
anisotropy where the FRK WT SH2 was titrated into the reaction and the anisotropy values had 
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increased until they plateaued indicating that all of the peptide (FRK C terminus, 
ETDSS(pY)SDANN) had been bound (Figure 5.8.2.2.1). From this the Kd value was interpreted to 
be 0.4 M as was calculated by fitting a sigmoidal curve by regression analysis. This data indicates 
that the FRK WT SH2 domain and SH2 consensus peptide can interact with high affinity (Figure 
5.8.2.2.1). 
 
 
 
 
 
 
 
 
 
Figure 5.8.2.2 1 
Rotational anisotropy was used to measure the interaction between FRK WT SH2 and consensus 
peptide. Anisotrpoy data was normalized to fraction of consensus peptide bound and a Kd value 
was found by regression analysis by fitting a sigmoidal curve to the average of three different 
experiments. Kd value = 0.4 M. 
5.8.3 Anisotropy Data for Interaction of GST and SH2 binding Peptides 
The FRK constructs utilized were GST fusion proteins therefore, experiments were also performed 
with the GST protein alone in 80 M concentrations to confirm that the interactions are specific to 
the SH2 domain of FRK and not GST. According to the results no binding was seen between GST 
and any of the SH2 domain specific peptides (Figure 5.8.3.1, 5.8.3.2). 
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Figure 5.8.3 1 
Anisotropy data for interaction with the FRK SH2 domain consensus peptide indicating no binding 
is occurring. 
 
 
 
 
 
 
 
 
Figure 5.8.3 2 
Anisotropy data for interaction with the FRK C terminus peptide indicating no binding is 
occurring. 
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5.8.4 FRK S145R SH2 Domain Interactions 
5.8.4.1 FRK S145R SH2 Domain Interaction with FRK C Terminus 
The mutations that are found in the SH3 and SH2 domains have the potential to disrupt inter and 
intramolecular interactions. We hypothesized that theses mutations would disrupt these 
interactions. This was tested using rotational anisotropy with the help of Dr. Linda Chelico. 
FRK S145R SH2 shows a specific binding with its own C terminus as exhibited by rotational 
anisotropy where the FRK S145R SH2 was titrated into the reaction and the anisotropy values had 
increased until they plateaued indicating that all of the peptide (FRK C terminus, 
ETDSS(pY)SDANN) had been bound (Figure 5.8.4.1). From this the Kd value was interpreted to 
be 1.4 M as was calculated by fitting a sigmoidal curve by regression analysis. This data indicates 
that the FRK WT SH2 domain and FRK C terminus can interact with high affinity. 
 
 
 
 
 
 
 
 
 
Figure 5.8.4.1  
Rotational anisotropy was used to measure the interaction between FRK S145R SH2 and FRK C 
terminus. Anisotropy data was normalized to fraction of FRK C terminus bound and a Kd value 
was found by regression analysis by fitting a sigmoidal curve to the average of three different 
experiments. Kd value = 1.4 M. 
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5.8.4.2 FRK S145R SH2 Domain Interaction with Consensus Peptide 
FRK S145R SH2 shows a specific binding with its own C terminus as exhibited by rotational 
anisotropy where the FRK S145R SH2 was titrated into the reaction and the anisotropy values had 
increased until they plateaued indicating that all of the peptide (FRK consensus, HF(pY)ENI) had 
been bound   (Figure 5.8.4.2). From this the Kd value was interpreted to be 0.8 M as was 
calculated by fitting a sigmoidal curve by regression analysis. This data indicates that the FRK 
WT SH2 domain and FRK C terminus can interact with high affinity. 
 
 
 
 
 
 
 
 
 
 
Figure 5.8.4.2  
Rotational anisotropy was used to measure the interaction between FRK S145R SH2 and SH2 
consensus peptide. Anisotrpoy data was normalized to fraction of SH2 consensus peptide bound 
and a Kd value was found by regression analysis by fitting a sigmoidal curve to the average of 
three different experiments. Kd vaule = 0.8 M. 
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All Kd and standard error values are found in table 5.8.3.1. 
  Table 5.8.3.1 
All Kd and standard error values from rotational anisotropy experiments. 
 
 
 
 
6.0 Discussion: 
FRK is a non-receptor tyrosine kinase which is associated with the BFK family and has been seen 
to function as a tumor suppressor in breast cancer and glioma (Goel and Lukong, 2016). Cancer 
associated mutations found in BRK have been previously characterized but those which lie in FRK 
have not been investigated. Six FRK cancer associated mutations have been characterized in this 
study in terms of their effect on proliferation, migration, invasion, and signaling. What was found 
was that the phospho-STAT3 was elevated in the presence of the VF deletions mutant which 
possesses the highest kinase activity.  
6.1 Enzymatic Activity of BRK and FRK Mutations 
In the present study, cancer related mutations of BRK (Tsui and Miller, 2015) were compared to 
mutations of similar residues in FRK (Table 2). The effect of cancer related mutations in BRK 
were assessed via western blot utilizing a phospho-tyrosine antibody in Figure 5.2 and were 
compared to the mutation of those similar residues in FRK (Figure 5.1). Through the comparison 
of the tyrosine kinase activation, we observed that the mutations of these similar residues have 
differing effects between FRK and BRK. Only two mutations of the conserved FRK residues 
altered the kinase activity of FRK. The mutations which exhibited similar effects in both proteins 
were the V253M (BRK), V295M (FRK), N317S (BRK), and N359I (FRK). V253M and N317S 
completely abolished kinase activity in BRK, whereas V295M reduced activity and N359I 
Interaction: FRK SH2 Kd () Error 
WT SH2 and FRK C terminus 2.5 0.30 
WT SH2 and Consensus Peptide 0.4 0.08 
S145R SH2 and FRK C terminus 1.4 0.15 
S145R SH2 and Consensus 
peptide 0.8 0.06 
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inactivated FRK. The N317 (BRK) and N359 (FRK) completely inactivate kinase activity of both 
proteins because this asparagine lies in a critical motif which is required for enzyme activity 
(Welsh et al., 2004).  The biological importance of V253 (BRK) and V295 (FRK) is not currently 
known. 
6.2 Cancer-Associated FRK Mutation Enzymatic Activity  
6.2 FRK Cancer-Associated Mutation Activity in HEK293 Cells 
The six-cancer related FRK mutations studied were, R64P, K87N, S145R, K265R, N359I, and 
V(378)F(379)del (Figure 5.2.1 and 5.2.2). Mutations in the SH3 domain and the SH2 domain 
(R64P, K87N, S145R) all exhibited no effect on kinase activity. The lone mutation in the SH2 
domain S145R was found in a suspected phospho-tyrosine binding motif FLIRES. This mutation 
is thought to interrupt the interaction between target phospho-tyrosines and the FRK SH2 domain 
and was expected to increase kinase activity due to the loss of regulation through Y497. Previous 
studies performed on Abl kinase, reveal that mutations in this motif cause the  reduced ability of 
the SH2 domain to interact with target phospho-tyrosines (Mayer et al., 1992) . 
The FRK, VF del mutation exhibited a drastic increase in kinase activity; however, the mechanism 
which causes this increase is not currently understood. This deletion lies down stream of a 
conserved motif DFG which aids in the binding of ATP. This deletion may disrupt how ATP 
interacts with the kinase domain resulting in increased activity.  
Two mutations showed reduced kinase activity, those being K265R, and N359I. The ATP binding 
lysine in FRK is K262, so it is possible that K265 may play a lesser role in ATP binding and could 
explain the reduction in kinase activity. The N359I mutation abolishes kinase activity due to its 
placement in the motif critical for enzyme activity. This mutation lies in a highly conserved region 
among the BFK family. This asparagine may interact directly with ATP and with a critical motif 
“HRD”. The aspartate residue has been shown to be the catalytic residue aiding the breakdown of 
ATP. Mutating the asparagine to isoleucine disrupts the interaction between both ATP and the 
aspartate of the HRD motif which results in abolished kinase activity.  
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6.3 Effect of Cancer-Associated Mutations on Cell Proliferation and Cell Migration 
We next investigated the effect of each of these mutations on the rate of cell growth (Figure 5.4.2). 
We initially predicted that the mutants with elevated kinase activity would possess an increased 
anti-proliferative activity. Transducing wild type FRK into MDA-MB-231 cells resulted in a 
decreased rate of cell proliferation which is consistent with what has been seen in previous studies 
(Ogunbolude et al., 2017b). The mutation studied which exhibited elevated kinase activity was the 
VF deletion which was expected to enhance the anti-proliferative effects of FRK. The mutations 
which result in decreased kinase activity were K265R, N359I were expected to diminish the 
function of FRK. All mutations resulted in reduced cell proliferation compared to the MDA-MB-
231 cell line but the rates if proliferation were not statistically different from the wild type FRK. 
Migration was then analyzed using a wound healing assay (Figure 5.5.1). The wild type FRK 
resulted in a significant decrease in the rate of wound closure which is significant with past findings 
(p value < 0.001) (Ogunbolude et al., 2017b). Mutations R64P, K265R, and N359I all behaved in 
a similar manner which exhibited an increased migration rate compared to wild type FRK and 
resulted in a wound 38-42% open which is significant compared to the wild type FRK and VF 
mutation (p value < 0.05). The VF Mutation showed a slower rate of migration compared to the 
other mutations but even with its heightened activity it was not statistically different from the wild 
type FRK. These results surrounding the effects on cell proliferation and migration indicate that 
the effects that FRK exerts on these cellular processes are not kinase dependent.  
6.4 Effect of Mutations on Cell Invasion 
The invasion was assessed using a Boyden chamber coated in extracellular matrix and 
polycarbonate membrane with an 8.0 m pore size. The cells used were the MDA-MB-231, and 
MDA-MB-231 cell lines stably expressing FRK WT, FRK R64P, FRK K265R, and FRK VF 
(Figure 5.6.1). The MDA-MB-231 control produced the highest number of migratory cells and 
the FRK WT stable cell line had the fewest migratory cells (p value < 0.05) which is consistent 
with what our lab has found previously (Ogunbolude et al., 2017). We hypothesized that the 
activity of each mutation would directly affect the rates of invasion with the higher activity 
mutations (R64P, VF) providing anti-invasive properties where the lower activity mutations 
(K265R, N359I) reduce the anti-invasive effects of FRK in breast cancer. FRK WT was the only 
test which showed a reduction in cell invasion while all mutations tested all resulted in a similar 
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number of cells which were able to migrate through the membrane as the MDA-MB-231 control. 
This indicates that the level of kinase activity of FRK is not the only factor that affects the invasive 
potential of these stable cell lines. 
6.5 Effect of FRK Mutations of Cell Signaling Molecules 
6.5.1 Effect Seen in MDA-MB-231 Stable Cell Lines 
The signaling molecules analyzed were STAT3, and p-STAT3 (Y705), JNK, p-JNK (Y185), c-
Jun, p-c-Jun (S63), and AKT, p-AKT (S473) which have all been seen to be altered due to FRK 
expression in breast cancer and glioblastoma (Ogunbolude et al., 2017; Zhou et al., 2012). 
Increased activation in any of these signalling molecules would increase cell proliferation and 
invasive potential of these cell lines. There was no change seen in the selected signalling molecules 
within the stable cell lines. This could be due the level of mutagenicity associated with the MDA-
MB-231 cell line or the lack of FRK kinase activity as shown previously which suggests that FRK 
alters these signaling pathways in a kinase dependent manner. If FRK expression had remained it 
would be expected that the STAT3 phosphorylation would have been reduced in a kinase 
dependant manner as shown in Ogunbolude et al., 2017, which would have also reduced the growth 
capabilities of the stable cell line. Perhaps a transient transfection into MDA-MB-231 cells would 
produce FRK with kinase activity and result in a possible effect on these signaling molecules.  
6.5.2 Effect Seen in Transiently Transfected HEK293 Cells 
The same signaling molecules were tested for by transiently transfecting HEK 293 cells which 
produced differing results compared to the MDA-MB-231 stable cell lines (Figure 5.7.2.1). The 
main effect occurred in the STAT3 and p-STAT3 trials. There was no p-STAT3 detected in the 
HEK293 cell line where WT FRK and all mutations except for N359I producing higher levels of 
p-STAT3. The kinase dead mutant was unable to induce STAT3 phosphorylation where all other 
mutants were able. This observation suggests that FRK is capable of increasing p-STAT3 levels 
in a kinase dependent manner. This was highlighted by the increased p-STAT3 induction by the 
VF mutant which produced significantly higher levels of p-STAT than all other mutations. No 
other statistically significant event was detected in any of the other signaling molecule tests 
including JNK, c-Jun, and AKT.  The significance of the induction of STAT3 phosphorylation is 
that STAT3 is responsible for the transcription of genes required for growth and cell survival. In 
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the context of HEK293 cells, the introduction of FRK may increase the growth rate of these cells 
through the activation of STAT3. 
6.6 FRK Cancer-Associated Mutation Activity in MDA-MB-231 Cells 
The kinase activity of these FRK cancer-associated mutations was also assessed in the MDA-MB-
231 stable cell lines. Surprisingly, none of the mutations nor the WT FRK in MDA-MB-231 cells 
showed any activity, where the control FRK WT transiently expressed in HEK293 cells showed 
proved to be active. This could possibly be because the MDA-MB-231 cells express higher levels 
of a phosphatase that dephosphorylates the Y387 in FRK which is the autophosphorylation site. 
This could also be due to the use of polyclonal experimentation. As the cells were passaged, the 
level of FRK activity and expression slowly decreased . The cell population may have been overrun 
by the fastest growing clone which expressed FRK in the level shown in figure 5.7.3. This 
decreased FRK expression could explain the results seen in the invasion assay. 
6.7 Rotational Anisotropy 
Rotational anisotropy was used to analyze the binding of each FRK domain to a peptide sequence 
which was thought to interact with each domain. Two peptides were used for each domain where 
the SH3 peptide was paired with either a peptide possessing PXXP from BRCA1 or PTEN. The 
SH2 domain was paired with peptide sequences possessing a phosphorylated tyrosine near the 
center of the peptide. These peptides were from the C terminus of FRK and what had been 
experimentally determined to be the consensus FRK SH2 binding sequence.  
6.7.1 FRK WT SH3 Domain Interactions 
The FRK SH3 domain was tested for binding to peptides derived from PTEN and BRCA1 at 
increasing peptide concentrations of 1.3 M at each titration. Unfortunately, neither of the peptides 
was capable of binding to the FRK SH3 domain. The SH3 domain may interact with its target in 
a different manner than originally thought. In these cases, the target may need to be folded to 
provide the correct binding sequence. 
6.7.2 FRK WT SH2 Domain Interactions 
The FRK SH2 domain was used at differing concentrations for each peptide. For the SH2 
consensus peptide, FRK WT SH2 was added at 0.6 M at each titration and for the FRK C 
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terminus, FRK WT SH2 was added at 0.1 M at each titration. Interactions were seen for each 
peptide. The Kd associated for the interaction with the SH2 consensus peptide was 0.4 M and the 
Kd for the FRK C terminus interaction was 2.5 M. Identical experiments were performed for GST 
alone as the FRK constructs were fused to GST. No binding was observed for the GST alone 
experiments.  
6.7.3 FRK S145R SH2 Domain Interactions 
S145R mutant was added at concentrations of 0.2 M at each titration and interacted with both 
peptides. The Kd for the consensus peptide was 0.8 M and the Kd for the FRK C terminus was 1.4 
M. These numbers are slightly different from the Kds for the FRK WT SH2 domain but there is 
not a large enough of a change to say they are behaving differently. It was surprising to see the 
S145R mutant binding to the SH2 peptides, however, this indicates that S145 is not the only 
important residue involved in phosphotyrosine binding. These results indicate that the S145R 
mutation in FRK does not have the same effect on phosphotyrosine binding as this analogous 
mutation in Abl kinase had. Amino acids in the FLIRES motif may have differential roles in the 
binding of phosphotyrosines in different kinases. 
7.0 Conclusions: 
A series of FRK cancer-associated mutations were generated where their kinase activity, effect on 
cell proliferation, migration, invasion, signaling molecules, and interactions with SH3 and SH2 
binding peptides were all assessed. The activities of the mutations transiently expressed in 
HEK293 showed significant variation for a number of mutations although, three of the mutations 
showed no change compared to the wild type FRK. The three mutations which showed no change 
in kinase activity were R64P, K87N, and S145R. Two mutations exhibited a reduction of kinase 
activity those being K265R, and N359I with the latter showing no kinase activity. The last 
remaining mutation is the VF deletion in the kinase domain, which show 3.5-fold increase in kinase 
activity.  
Four mutations were chosen to be expressed stably in MDA-MB-231 cells and activity was also 
tested for. Unfortunately, none of the mutations exhibited any kinase activity when assessed 
through Western blot. Still the stable cell lines were used to test cell proliferation, migration and 
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invasion. All cancer associated mutations resulted in decreased cell proliferation but were no 
different from each other. Wild type FRK had the most drastic reduction in cell migration that was 
equal to that of VF. R64P, K265R, and N359I all showed slightly less effectiveness in reducing 
cell migration. The invasion assay shows that only the wild type FRK was capable of reducing the 
invasiveness of MDA-MB-231 cells.  
The effect of these mutations were also tested as to how they can alter the phosphorylated levels 
of STAT3, c-Jun, JNK, and AKT. The stable MDA-MB-231 cell lines showed no change in 
phosphorylation levels of these proteins. The same experiments were performed on HEK293 cells 
transiently expressing all mutations. Only p-STAT3 Y705 levels were altered where all FRK 
constructs showed increased p-STAT3 levels with VF showing the largest increase with the 
exception of N359I which had no effect on STAT3 phosphorylation. This indicated that this event 
occurs in a kinase dependent manner. 
Interaction experiments were conducted utilizing the three mutations found in the SH3 and SH2 
domains. The SH3 peptides designed were identified from known interaction partners PTEN and 
BRCA1 and the SH2 peptides were from the C terminus of FRK and the consensus SH2 peptide 
determined by Zhao et al. (Zhao et al., 2013). The SH3 domain unfortunately did not show any 
interaction with the peptides associated with PTEN or BRCA1. The wild type FRK SH2 domain 
did interact with both the C terminus of FRK and the consensus SH2 peptide with a Kd of 2.5 M 
and 0.4 M respectively. The S145R SH2 mutation also associated with both the C terminus and 
consensus peptides with a Kd of 1.4 M and 0.8 M. These numbers are close enough to state that 
these domains are behaving in a similar manner, which means that the S145R mutation does not 
have a significant effect of phosphotyrosine binding.    
8.0 Future Directions 
Considering how the mutations chosen to be stably expressed in MDA-MB-231 cells showed no 
activity, they should be expressed in either a less mutagenic breast cancer such as cell line such as 
MCF7 or using a Tet on system. In order to express the FRK mutants in MCF7 first they wild type 
FRK would have to be knocked out so that the only FRK effect seen will be from the specific 
mutations. Stable cell lines should also be generated in the HEP3B liver cancer cell line to 
determine if the effects produced by the FRK mutations are exclusive to the tissue type or are 
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solely based on the kinase activity. The Tet on system may be important for expressing the FRK 
mutants in MDA-MB-231 cells as it may be a possibility that the stable overexpression of FRK 
would result in additional changes occurring within the cell that cause FRK activity to be shut 
down.  
The binding experiments resulted in equal binding between the wild type FRK SH2 domain and 
the S145R SH2 mutation. This mutation was hypothesized to disrupt the interaction between FRK 
and may indicate that phosphorylated tyrosine residues. This the different residues found within 
the FLIRES motif may play different roles in the binding of phosphotyrosines in different kinases. 
To discover which residues are of the utmost importance, each residue should be mutated 
individually, and the same rotational anisotropy experiments redone to observe changes in binding. 
To also be absolutely certain that this motif is required for phosphotyrosine binding, the entire 
motif should be removed to observe that no peptide binds. The SH3 peptides also showed no 
interaction with the peptides associated with PTEN or BRCA1 so instead of taking peptides 15 
amino acids long, the entire region where FRK binds to these proteins could be expressed by a 
bacterial, or SF9 expression vector and tagged with fluorescein. The rotational anisotropy 
experiments would then be repeated to observe binding with the entire region that FRK has been 
seen to associate with. Lastly, additional binding experiments should be performed using 
unphosphorylated peptides as a negative control.  
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